Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Allergan, Inc. (EHT/AGN 0001 license)
2010 · Licensing/Option · $413M · Terminated
Announcement Sentiment
50
Neutral / mixed
BMS/Allergan global exclusive license for AGN-209323: $40M upfront + up to $373M milestones + worldwide royalties. Originally licensed from ExonHit.
Key facts
- Announced Mar 31, 2010
- Deal value $413M
- Deal type Licensing/Option
- Therapeutic area Neuropathic pain
- Indications Neuropathic pain
- Key assets AGN-209323 (EHT/AGN 0001)
- Mechanism Small molecule (Phase II-ready)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals